Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer
LD Mellby, AP Nyberg, JS Johansen… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year
survival of< 10% because of diffuse symptoms leading to late-stage diagnosis. That survival …
survival of< 10% because of diffuse symptoms leading to late-stage diagnosis. That survival …
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
I Hochnadel, U Kossatz-Boehlert… - Human Vaccines & …, 2017 - Taylor & Francis
Hepatobiliary and pancreatic cancers along with other gastrointestinal malignancies remain
the leading cause of cancer-related deaths worldwide. Strategies developed in the recent …
the leading cause of cancer-related deaths worldwide. Strategies developed in the recent …
[PDF][PDF] Anticancer effect of Phellinus linteus; potential clinical application in treating pancreatic ductal adenocarcinoma
CM Kang, HK Hwnag, SH Choi, WJ Lee - 2013 - core.ac.uk
Pancreatic cancer (ductal adenocarcinoma) is one of the most lethal malignancies in
gastrointestinal system. Till now, only margin-negative pancreatectomy is known to be the …
gastrointestinal system. Till now, only margin-negative pancreatectomy is known to be the …
[HTML][HTML] A phase II trial of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475)+ lenalidomide+ dexamethasone as post autologous stem cell transplant …
Introduction: High-risk multiple myeloma (HRMM) patients (pts) will relapse post-autologous
stem cell transplant (ASCT) within 1-2 years. Blockade of the PD-1/PD-L1 interaction on …
stem cell transplant (ASCT) within 1-2 years. Blockade of the PD-1/PD-L1 interaction on …
[PDF][PDF] Epigenetic priming for Immune therapy in ER-positive breast cancer in biomarker select population
PN Munster, MO Kim - cdn.clinicaltrials.gov
Epigenetic priming for Immune therapy in ER-positive breast cancer in biomarker select
population NCT# 04190056 Page 1 Proprietary and Confidential The information in this …
population NCT# 04190056 Page 1 Proprietary and Confidential The information in this …
[PDF][PDF] Phase I Study of MK-3475 in Combination with BCG for Patients with High Risk Superficial Bladder Cancer
Objective: To determine the safety of administering MK-3475 at a fixed dose of 200 mg every
three weeks in conjunction with intravesicular BCG treatment in high risk non-muscle …
three weeks in conjunction with intravesicular BCG treatment in high risk non-muscle …
Methods, arrays and uses thereof
P Delfani, LD Mellby, A Carlsson, B Elleby - US Patent 11,320,436, 2022 - Google Patents
The present invention provides a method for diagnosing or determining a pancreatic cancer-
associated disease state comprising or consisting of the steps of:(a) providing a sample from …
associated disease state comprising or consisting of the steps of:(a) providing a sample from …
[PDF][PDF] A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma …
T CONFIDENTIAL, PPOF MERCK - 2022 - aacr.figshare.com
Merck & Co., Inc. policy on posting of redacted study protocols on journal websites is
described in Guidelines for Publicati Page 1 Merck & Co., Inc. policy on posting of redacted …
described in Guidelines for Publicati Page 1 Merck & Co., Inc. policy on posting of redacted …
Methods, arrays and uses thereof
C Borrebaeck, LD Mellby, A Nyberg… - US Patent App. 16 …, 2019 - Google Patents
US20190382849A1 - Methods, arrays and uses thereof - Google Patents
US20190382849A1 - Methods, arrays and uses thereof - Google Patents Methods, arrays …
US20190382849A1 - Methods, arrays and uses thereof - Google Patents Methods, arrays …
[PDF][PDF] Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)(KEYNOTE-199)
T CONFIDENTIAL, PPOF MERCK - 2021 - cdn.clinicaltrials.gov
Official Protocol Title: NCT number: Document Date: 12-Aug-2021 NCT02787005 Page 1
Official Protocol Title: NCT number: Document Date: Phase II Trial of Pembrolizumab (MK-3475) …
Official Protocol Title: NCT number: Document Date: Phase II Trial of Pembrolizumab (MK-3475) …